Medical economics

Pfizer and Moderna won't be the only ones to reap huge payday

Pfizer and Moderna appear to be the clear leaders in the race for a COVID-19 vaccine. Pfizer has already begun distribution, and Moderna's entry is on the brink of FDA approval, which would put the two at least weeks ahead ...

Medications

First report card on biosimilars in oncology

Researchers have developed the first report card on biosimilars for three blockbuster cancer drugs marketed by Genentech/Roche: Rituxan, Avastin and Herceptin. In a Policy Review in The Lancet Oncology, Y. Tony Yang, a professor ...

Psychology & Psychiatry

Be generous, live longer

The act of giving and receiving increases well-being: the recipient benefits directly from the gift, and the giver benefits indirectly through emotional satisfaction. A new study published in the journal PNAS now suggests ...

Medical economics

German vaccine maker CureVac surges almost 250% in Nasdaq debut

Shares of German biotech company CureVac, which is developing a leading coronavirus vaccine candidate, rocketed Friday in its first day of trading in New York after raising more than $200 million in an initial public offering.

Psychology & Psychiatry

Stemming the spread of misinformation on social media

The bad news, not that anyone needs more of it: The dangers of COVID-19 could worsen if misinformation on social media continues to spread unchecked. Essentially, what people choose to share on social media about the pandemic ...

page 7 from 20